MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
EOLS - Evolus Inc
$12.51
0.40(3.30%)12:27:47 AM 3/2/2021
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • RSI is at a high level of 72. A high level of RSI indicates the stock is overbought.
  • MACD is crossing MACD signal line at 0.4. MACD crossing signal line is bullish signal.
Stock Statistics
MarketCap421.2M
PE Ratio-6.2
PEG Ratio-0.1
P/B11.6
P/S (ttm)7.4
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %15%
Held by Institutions %23%
1 Day Vol Adjusted Return0.2
1 Month Vol Adjusted Return5.4
3 Month Vol Adjusted Return21.1
6 Month Vol Adjusted Return23.7
20 Days SMA Price ZScore1.8
50 Days SMA Price ZScore2.4
12 -26 Days PPO18.7
1 Month Average Short Volume Ratio47.3
1 Day Volume Change ZScore-0.3
1 Month Daily Vol16.9
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    03/1/2021EOLS
    Is a Surprise Coming for Evolus (EOLS) This Earnings Season?

    Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    02/26/2021EOLS
    Evolus Announces Promotion of Crystal Muilenburg to Chief Marketing Officer

    NEWPORT BEACH, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the promotion of Crystal Muilenburg from VP, Corporate Communications & PR to Chief Marketing Officer effective today. Crystal will oversee the U.S. marketing organization and establish the company’s international infrastructure to support the expansion of Nuceiva™ in all Evolus licensed te...

    02/23/2021EOLS
    Evolus Announces Preliminary, Unaudited, Fourth Quarter and Full Year 2020 Net Revenue

    Q4 2020 Net Revenue of $20.6 Million Increased 16% Over Q3 2020NEWPORT BEACH, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS) today announced its preliminary, unaudited, net revenues for the fourth quarter and full year ended December 31, 2020. The preliminary unaudited results described in this press release are estimates only and are subject to revision until the company reports its full financial results for the fourth quarter and full year 2020. “We delivered another qu...

    02/19/2021EOLS
    EOLS Stock: The Big News That Has Evolus Shares Skyrocketing Today

    Evolus (NASDAQ:EOLS) stock was on the rise Friday following news that it’s no longer dealing with lawsuits from AbbVie (NYSE:ABBV) and Medytox. Source: Bukhta Yurii / Shutterstock.com The legal battle between the companies was over Evolus selling Jeuveau. This is a prescription drug that is injected into muscles to temporarily reduce severe lines around the eyes. The allegations claimed that Evolus misused trade secrets for Jeuveau. The news today is that AbbVie and Medytox are dropping all clai...

    02/19/2021EOLS
    Evolus to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

    NEWPORT BEACH, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in the 10th Annual SVB Leerink Global Healthcare Conference. Event: 10th Annual SVB Leerink Global Healthcare Conference Format: Fireside Chat & 1x1 Meetings Date: Wednesday, February 24, 2021 Time: 1:00pm – 1:30pm ET Location: Evolus Live Fi...

    02/19/2021EOLS
    Evolus Shares Surge After Settling Jeuveau Related Litigation With AbbVie, Medytox

    Evolus Inc (NASDAQ: EOLS), AbbVie Inc (NYSE: ABBV), and Medytox announced settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the sale of Jeuveau. It is a prescription medicine injected into muscles and used in adults temporarily to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines). A California court case filed by Medytox against Evolus will be dismissed. Under ...

    02/19/2021EOLS
    AbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation

    AbbVie (NYSE: ABBV), Evolus (NASDAQ: EOLS) and Medytox announce settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the sale of Jeuveau®, between the companies. A California court case filed by Medytox against Evolus will be dismissed.

    02/17/2021EOLS
    When Can We Expect A Profit From Evolus, Inc. (NASDAQ:EOLS)?

    Evolus, Inc. ( NASDAQ:EOLS ) is possibly approaching a major achievement in its business, so we would like to shine...